Myeloma and AL amyloidosis ASH 2021 preview

• Challenges in Multiple Myeloma Treatment – Maria-Victoria Mateos. Click here to read the abstract.
• Challenges in Multiple Myeloma Treatment – Live Q&A – Maria-Victoria Mateos, Noopur S. Raje, MD., Ashley E. Rosko, MD. Click here to read the abstract.
• Minimal Residual Disease in Multiple Myeloma – Why, When, Where, and How-Noopur S. Raje, MD. Click here to read the abstract.
• A Glimpse into the Future of Myeloma Patient Management- Hearn Jay Cho, MD., PhD., Amrita Y. Krishnan, MD, Elisabet E. Manasanch, MD., Paul G. Richardson, MD., Nina Shah, MD., A. Keith Stewart, MBChB. Click here to read the abstract
• Multiple Myeloma Real- World Data for Research (HARMONY)- Mario Boccadoro. Click here to read the abstract.

• Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin – Jacob P. Laubach.  Click here to read the abstract.
• Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 – Herve Avet Loiseau, MD, PhD. Click here to read the abstract.
• Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant- Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial – Hartmut GoldSchmidt, MD. Click here to read the abstract.
• Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial– Martin F. Kaiser, MD, FRCP, FRCPath. Click here to read the abstract.
• Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial – Laura Rosinol. Click here to read the abstract.
• First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios- Rafael Fonseca. Click here to read the abstract.
• Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study– Kaz Groen, MD. Click here to read the abstract.
• Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly- Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial – Harmut GoldSchmidt, MD. Click here to read the abstract.
• Redefining Frontline Therapy in Transplant Ineligible Multiple Myeloma Patients: Maia 5-Year Update Including Overall Survival – Thomas S. Lin, Md, PhD. Click here to read the abstract.

• Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.– Shaji K. Kumar, MD. Click here to read the abstract.
• Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial – Sagar Lonial, MD, FACP. Click here to read the abstract.
• DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma- Natalie S. Callander, MD. Click here to read about the abstract.
• Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study- Dan. T. Vogl. Click here to read the abstract.
• Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma – Jonathan L. Kaufman, MD. Click here to read the abstract.

• Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials- Gordon Cook, MD. Click here to read the abstract.
• Treatment of Older Adult to Frail Patients with Multiple Myeloma- Ashley E. Rosko, MD. Click here to read the abstract.

Bi specifics:

• Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study – Suzanne Trudel, MD. Click here to read the abstract.
• Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma – Ajai Chari, MD. Click here to read the abstract.
• Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma – Amrita Y. Krishna, MD. Click here to read the abstract.
• Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) – Jeffrey A. Zonder, MD. Click here to read the abstract.
• Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1 – Michael Sebag, MD, PhD. Click here to read the abstract.
• Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma -Philippe Moreau, MD. Click here to read the abstract.
• A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma- Shaji K. Kumar, MD. Click here to read the abstract.
• ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma – Sammichell Stefano, PhD. Click here to read the abstract.
• Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies(BiAbs)- Tarek H. Mouhieddine, MD. Click here to read the abstract.

CAR-T cells:

• Advances in CAR-T Cell Therapy Across Hematologic Malignancies: from Pipeline to Clinical Practice – Jesús G. Berdeja, Michael R. Bishop, MD, Jae H Park, MD. Click here to read the abstract.
• A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma – Ranjan Maity, PhD. Click here to read the abstract.
• A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma. – Chunrui Li, MD, PhD. Click here to read the abstract.
• Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma– Noopur S. Raje, MD. Click here to read the abstract.
• Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple Myeloma– Thomas Martin. Click here to read the abstract.
• Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study – Maria-Victoria Mateos. Click here to read the abstract.
• Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma- Andrew J. Cowan, MD. Click here to read the abstract.
• Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) – Aina Oliver- Caldés, MD. Click here to read the abstract.
• Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma – Sham Mailankody, MBBS. Click here to read the abstract.
• Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma- Sham Mailankody, MBBS. Click here to read the abstract.

Novel therapies and prognosis:

• Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States – Bharat Nandakumar. Click here to read the abstract.

• Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected by These Diseases? – Mycal casey, DO. Click here to read the abstract.
• 4118 – Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years. (PAPER) Click here to read the abstract.

• 4116 – Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma. (PAPER) Click here to read the abstract.
• Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma – Nancy Gillis, MD. Click here to read the abstract.
• Clinical and Biological Factors That Affect Presentation and Outcomes in Multiple Myeloma Patients with Excess Body Weight – Beatrice Razzo, MD. Click here to read the abstract.
• Roots of Socioeconomic and Biological Disparities Among Hispanics with Multiple Myeloma- Rigoberto De Jesus Pizarro, MD. Click here to read the abstract.
• Identifying Disparities in Survival Among Older Adults with Multiple Myeloma Based on Rural Versus Urban Residence – Sarah Addison, BS. Click here to read the abstract.
• Overcoming Barriers to Equitable Care for Patients with Multiple Myeloma– Sikander Ailawadhi, MD, Craig E. Cole, MD, Stinchon R Michael Jr., RPh. Click here to read the abstract.
• How Can We Ensure That Everyone Who Needs A Transplant Can Get One? – Live Q&A–Andrew S. Artz, MD MS, Navneet S. Majhail, MD, Vanderson Rocha, MD, PhD. Click here to read the abstract.

• Is PFS the Right Endpoint to Assess Outcome of Maintenance Studies in Multiple Myeloma? Results of a Patient Survey Highlight Quality-of-Life As an Equally Important Outcome Measure – Anna Fleischer, MD. Click here to read the abstract.
• A is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey – Noa Biran, MD, Suzanne Lentzsch, MD, PhD Ajay K. Nooka. Click here to read the abstract.
• Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans – Rajshekhar Chakraborty, MD. Click here to read the abstract.

• Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment. – Oliver Van Oekelen, MD MSc. Click here to read the abstract.
• Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study – Nathanael R Fillmore, PhD. Click here to read the abstract.

• Smouldering Multiple Myeloma- Evolving Diagnostic Criteria and Treatment Strategies- Rahma M Warsame, MD. Click here to read the abstract.
• Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes – Shankara Anand, MS. Click here to read the abstract.

• Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study – Raymond Comenzo, MD. Click here to read the abstract.
• Safety and Tolerability of Cael-101 in Combination with Anti-Plasma Cell Dyscrasia Therapy in Patients with AL Amyloidosis: 1- Year Results from an Open-Label Phase 2 Trial- Jason Valent. Click here to read the abstract.
• Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design- Morie A Gertz, MD, MACP. Click here to read the abstract.
• Belantamab Mafadotin in Patients with Relapsed/Refractory AL Amyloidosis with Myeloma – Yifei Zhang, MD. Click here to read the abstract.
• Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy – Blessie Elizabeth Nelson, MBBS. Click here to read the abstract.
• Treatment Landscape for AL Amyloidosis: Daratumumab plus hyaluronidase- Rachel Ershler, MD. Click here to read the abstract.
• Treatment Landscape for AL Amyloidosis- Clinical Discussant – Vaishali Sanchorawala, MD. Click here to read the abstract.